Denosumab-associated osteonecrosis of the jaw: earlier onset after switch from zoledronic acid

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1920卷 / 1期
关键词：
D O I：
10.1007/s40278-022-21546-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 9
相关论文
共 50 条
  • [21] Denosumab/zoledronic acidMedication-related jaw osteonecrosis: 2 case reports
    Reactions Weekly, 2019, 1750 (1) : 109 - 109
  • [22] Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid
    Calvo-Villas, Jose Manuel
    Torres, Maria Tapia
    Rodriguez, Jose Govantes
    de Granda, Elena Carreter
    Guillen, Francisco Sicilia
    MEDICINA CLINICA, 2006, 127 (15): : 576 - 579
  • [23] Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
    Hiroaki Ikesue
    Kohei Doi
    Mayu Morimoto
    Masaki Hirabatake
    Nobuyuki Muroi
    Shinsuke Yamamoto
    Toshihiko Takenobu
    Tohru Hashida
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 871 - 877
  • [24] Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
    Ikesue, Hiroaki
    Doi, Kohei
    Morimoto, Mayu
    Hirabatake, Masaki
    Muroi, Nobuyuki
    Yamamoto, Shinsuke
    Takenobu, Toshihiko
    Hashida, Tohru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (06) : 871 - 877
  • [25] Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
    Alexander Wick
    Philipp Bankosegger
    Sven Otto
    Bettina Hohlweg-Majert
    Timm Steiner
    Florian Probst
    Oliver Ristow
    Christoph Pautke
    Clinical Oral Investigations, 2022, 26 : 2839 - 2852
  • [26] Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
    Wick, Alexander
    Bankosegger, Philipp
    Otto, Sven
    Hohlweg-Majert, Bettina
    Steiner, Timm
    Probst, Florian
    Ristow, Oliver
    Pautke, Christoph
    CLINICAL ORAL INVESTIGATIONS, 2022, 26 (03) : 2839 - 2852
  • [27] Bevacizumab/denosumab/zoledronic-acidMedication-related osteonecrosis of the jaw: 3 case reports
    Reactions Weekly, 2023, 1981 (1) : 92 - 92
  • [28] An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid
    de Alexandria Santos, Danila S.
    de Sales Lima, Marco Vinicius
    Scherma, Alexandre do Prado
    Kitakawa, Darcio
    Magalhaes, Natalia de Castro
    Peralta, Felipe Silva
    das Chagas e Silva de Carvalho, Luis Felipe
    AMERICAN JOURNAL OF CASE REPORTS, 2020, 21 : 1 - 6
  • [29] Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment
    Fusco, Vittorio
    Loidoris, Anastasios
    Colella, Giuseppe
    Vescovi, Paolo
    Campisi, Giuseppina
    BREAST, 2010, 19 (05): : 432 - 433
  • [30] Experimental model of osteonecrosis of the jaw in rats treated with zoledronic acid
    Kolpakova, M. E.
    Zubareva, A. A.
    Artamonova, T. D.
    Lisovskaya, E. K.
    Chefu, S. G.
    Yagmurov, O. D.
    Yaremenko, A. I.
    Vlasov, T. D.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2017, 55 (02): : 156 - 159
12345